Immune Profiling for Cancer Immunotherapy Response

Description

In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.

Conditions

Cancer, Tumor, Solid, Hematologic Malignancy, Blood Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.

Immune Profiling for Cancer Immunotherapy Response

Immune Profiling for Cancer Immunotherapy Response

Condition
Cancer
Intervention / Treatment

-

Contacts and Locations

Lebanon

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States, 03756

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
  • * Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).
  • * Pregnant women/fetuses/neonates
  • * Prisoners
  • * Decision-impaired individuals

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Dartmouth-Hitchcock Medical Center,

Brock C Christensen, PhD, PRINCIPAL_INVESTIGATOR, Dartmouth College

Study Record Dates

2026-01-01